IL1B and myocardial infarction: Most importantly, it has been recently demonstrated that patients with previous myocardial infarction, who received the monoclonal antibody targeting IL-1β selectively, had a 15% reduction of major adverse cardiovascular events (MACE) as well as a 17% reduction of MACE and hospitalization for unstable angina requiring urgent revascularization after 48 months of treatment [12].